Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johnathan M Lancaster

Showing results (41-50 of 73) with videos related to

Pageof 8
Sort By:
The Journal of Biological Chemistry|August 29, 2012
MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/NanogCheng-Xiong Xu, Meng Xu, Lei Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancersAndrew Berchuck, Edwin S Iversen, Johnathan M Lancaster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2019
Prediction of Distant Recurrence Using EndoPredict Among Women with ER<sup>+</sup>, HER2<sup>-</sup> Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy OnlyMartin Filipits, Peter Dubsky, Margaretha Rudas, et al.
Plos One|December 1, 2023
Prevalence of viral DNA in high-grade serous epithelial ovarian cancer and correlation with clinical outcomesSharon E Robertson, Maya Yasukawa, Douglas C Marchion, et al.
Gynecologic Oncology|July 24, 2013
Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrestEntidhar Al Sawah, Xin Chen, Douglas C Marchion, et al.
Plos One|November 23, 2021
Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomesDaryoush Saeed-Vafa, Douglas C Marchion, Susan M McCarthy, et al.
Journal of Gynecologic Oncology|February 23, 2012
BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatinNisha Bansal, Douglas C Marchion, Elona Bicaku, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 19, 2013
Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying henGustavo C Rodriguez, H John Barnes, Kenneth E Anderson, et al.
Gynecologic Oncology|October 29, 2011
The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatinHye Sook Chon, Douglas C Marchion, Yin Xiong, et al.
Oncology Reports|November 14, 2013
Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxelNing Chen, Hye Sook Chon, Yin Xiong, et al.
Pageof 8

Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
The Journal of Biological Chemistry|August 29, 2012
MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/NanogCheng-Xiong Xu, Meng Xu, Lei Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancersAndrew Berchuck, Edwin S Iversen, Johnathan M Lancaster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2019
Prediction of Distant Recurrence Using EndoPredict Among Women with ER<sup>+</sup>, HER2<sup>-</sup> Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy OnlyMartin Filipits, Peter Dubsky, Margaretha Rudas, et al.
Plos One|December 1, 2023
Prevalence of viral DNA in high-grade serous epithelial ovarian cancer and correlation with clinical outcomesSharon E Robertson, Maya Yasukawa, Douglas C Marchion, et al.
Gynecologic Oncology|July 24, 2013
Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrestEntidhar Al Sawah, Xin Chen, Douglas C Marchion, et al.
Plos One|November 23, 2021
Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomesDaryoush Saeed-Vafa, Douglas C Marchion, Susan M McCarthy, et al.
Journal of Gynecologic Oncology|February 23, 2012
BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatinNisha Bansal, Douglas C Marchion, Elona Bicaku, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 19, 2013
Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying henGustavo C Rodriguez, H John Barnes, Kenneth E Anderson, et al.
Gynecologic Oncology|October 29, 2011
The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatinHye Sook Chon, Douglas C Marchion, Yin Xiong, et al.
Oncology Reports|November 14, 2013
Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxelNing Chen, Hye Sook Chon, Yin Xiong, et al.
Pageof 8